Alcon Inc is a global leader in the eye care industry, specializing in the development and manufacturing of innovative products aimed at enhancing vision and eye health
The company offers a comprehensive range of surgical and vision care solutions, including advanced intraocular lenses, surgical instruments, contact lenses, and eye care products. With a commitment to improving patient outcomes and quality of life, Alcon employs cutting-edge technology and research to address various eye conditions and promote healthier vision for individuals around the world.
Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine month periods ending September 30, 2024. For the third quarter of 2024, sales were $2.4 billion, an increase of 6% on a reported and constant currency basis1, as compared to the same quarter of the previous year. Alcon reported diluted earnings per share of $0.53 and core diluted earnings per share2 of $0.81 in the third quarter of 2024.
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. launch of PRECISION7®, the only one-week replacement contact lens with the revolutionary 7-day ACTIV-FLO® System2 that provides 16 hours of outstanding comfort and precise vision, even on day 7.1
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, will showcase its latest clinical data and product innovations at the upcoming American Academy of Ophthalmology (AAO) 2024 annual meeting. Ophthalmologists, surgical staff, researchers, and industry leaders can visit Alcon at booth #4008 for hands-on demonstrations and engaging experiences.
Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and six month periods ending June 30, 2024. For the second quarter of 2024, sales were $2.5 billion, an increase of 3% on a reported basis and 6% on a constant currency basis1, as compared to the same quarter of the previous year. Alcon reported diluted earnings per share of $0.45 and core diluted earnings per share2 of $0.74 in the second quarter of 2024.
Japan’s Eisai Pharma formed a collaboration with SEED, a Pennsylvania biotech, to develop molecular glues for targeted protein degradation of disease-causing proteins. SEED is eligible to receive up to $1.5 billion in milestones plus royalties.
The resilience of the market was in full display on Monday after last week’s “historical comeback” by the market. The major index futures traded higher, albeit by a modest magnitude.
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that UNITY® Vitreoretinal Cataract System (VCS) and UNITY® Cataract System (CS) have received U.S. Food and Drug Administration (FDA) 510(k) clearance. These innovations are the first to be introduced from Alcon’s highly anticipated Unity portfolio.
Top performing large-cap stocks in the last week: MSTR, MNDY, ONON, SE, PODD, DELL, VOD, ALC, SMCI, CRBG. Analysts raise price targets & more positive news.
Alcon's recent upgrades and promising opportunities, including the BELKIN Vision acquisition, expanding glaucoma treatment options, enhanced PanOptix IOL, and market advancements in China.
